Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1698 • ACR Convergence 2021
Integrated Safety Analysis Update for Filgotinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Receiving Treatment over a Median of 2.2 Years
Kevin Winthrop¹, Yoshiya Tanaka², Tsutomu Takeuchi³, Alan Kivitz⁴, Mark Genovese⁵, Alena Pechonkina⁶, Franziska Matzkies⁶, Beatrix Bartok⁷, Kun Chen⁶, Deyuan Jiang⁶, Iyabode Tiamiyu⁶, Robin Besuyen⁸, Sander Strengholt⁹, Gerd Burmester¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Oregon Health & Science University, Portland, OR, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Div. Rheumatology, Keio University, Tokyo, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Gilead Sciences, Inc., Sunnyvale, CA, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Gilead Sciences, Inc., La Jolla, CA, ⁸Galapagos BV, Leiden, Netherlands, ⁹Galapagos, BV, New York, NY, ¹⁰Charité University Medicine Berlin, Berlin, Germany, ¹¹National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) significantly improved signs and symptoms of RA in Phase 2 and 3 trials,1–5 and FIL is…
Abstract Number: 1890 • ACR Convergence 2021
Cellular Origin and Functions of Osteoclasts in Inflammatory Arthritis
Hannah Nelson¹, Ellen Gravallese², Julia Charles¹ and Christian Jacome-Galarza¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Inflammatory arthritis (IA) is an autoimmune disease targeting multiple joints and characterized by joint destruction caused by osteoclasts (OC), leading to physical disability. However,…
Abstract Number: 1942 • ACR Convergence 2021
Occurrence of Basal Cell and Squamous Cell Carcinomas of the Skin Under Different DMARD Therapies
Imke Redeker¹, Peter Herzer², Cornelia Kühne³, Ilka Schwarze⁴, Martin Schaefer⁵ and Anja Strangfeld⁶, ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Scientific Advisory Board, Munich, Germany, ³Rheumatologist, Haldensleben, Germany, ⁴Rheumatologist, Leipzig, Germany, ⁵German Rheumatism Research Center, Berlin, Germany, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: Squamous and basal cell carcinomas are the most common malignancies of the skin; they are subsumed under non-melanoma skin cancer (NMSC). The risk of…
Abstract Number: 0011 • ACR Convergence 2021
Differential Inflammation-mediated Function of Prokineticin 2 in the Synovial Fibroblasts of Patients with Rheumatoid Arthritis Compared to Osteoarthritis
Kentaro Noda, Bianca Dufner and Rainer Straub, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: Prokineticin 2 (PK2) is a secreted protein involved in several pathological and physiological processes, including the regulation of inflammation, sickness behaviors, and the circadian…
Abstract Number: 0029 • ACR Convergence 2021
JAK1 Regulates Autophagy and Reinforces the Inflammatory and Autoimmune Potentials in Rheumatoid Arthritis Synovial Fibroblasts
Keita Ninagawa¹, Masaru Kato¹, Yuki Kudo², Masaru Yoshimura², Michihito Kono², Yuichiro Fujieda¹, Kenji Oku² and Tatsuya Atsumi³, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²1. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ³Hokkaido University, Sapporo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is pathologically characterized by autoimmunity against citrullinated proteins, proliferative synovitis, and ultimately joint destruction. Synovial fibroblasts (SFs) are, when activated, capable…
Abstract Number: 0051 • ACR Convergence 2021
Identification of Biomarkers and Deregulated Pathways in Psoriatic Arthritis Through Proteomic Analysis of Synovial Fluid
Jacqueline Lai¹, Sara Rahmati², Raam Sivakumar², Katerina Oikonomopoulou³, Fatima Abji⁴ and Vinod Chandran⁵, ¹McMaster University, Hamilton, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that currently lacks diagnostic biomarkers. We hypothesized that there are differences in the protein intensities in the…
Abstract Number: 0156 • ACR Convergence 2021
Tenosynovitis Detected by Power Doppler Ultrasound: A Differential Feature of Patients with Seronegative Rheumatoid Arthritis
Einer Sanchez Prado¹, Santiago Ruta², Laura Cuellar¹, Sebastian Magri³ and Rodrigo Garcia Salinas⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital San Martin de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, La Plata, ⁴Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: It is known that seronegative rheumatoid arthritis has different characteristics from seropositive RA. Objectives: To estimate the frequency of rheumatoid arthritis (RA) in a…
Abstract Number: 0268 • ACR Convergence 2021
Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, George Reed², Kevin Kane², Jeffrey Curtis³ and Joel Kremer⁴, ¹Columbia University, New York, NY, ²University of Massachusetts, Worcester, MA, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Albany Medical College, Latham, NY
Background/Purpose: Cardiovascular disease (CVD) risk scores incorporating measures of inflammation such as the Reynolds risk score (RRS) may be appropriate to predict CVD risk in…
Abstract Number: 0285 • ACR Convergence 2021
Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Reinder Raadsen¹, Romy Hansildaar¹, Maaike Heslinga², Arno van Kuijk¹ and Michael Nurmohamed³, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of developing, mainly ischemic cardiovascular diseases (CVD). This is partly explained by…
Abstract Number: 0459 • ACR Convergence 2021
CCN1: An Angiogenic Actor Implicated in the Structural Damages of Rheumatoid Arthritis
Jerome Avouac¹, Alexia Steelandt², Olivia Amiar², Agathe Leblond², Cindy Orvain², Anne Cauvet², Virginie Gonzalez² and Yannick Allanore¹, ¹Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²INSERM U1016, Institut Cochin, Paris, France
Background/Purpose: We have previously shown that decreased expression of the deacetylase sirtuin-1 (SIRT1) contributes to the proliferative, activated and proangiogenic profile of endothelial cells (EC)…
Abstract Number: 0564 • ACR Convergence 2021
Associations of Sinusitis, Pharyngitis, and Respiratory Tract Disease Burden with Incident Rheumatoid Arthritis
Vanessa Kronzer¹, Weixing Huang², Alessandra Zaccardelli², Cynthia Crowson³, John Davis¹, Robert Vassallo¹, Tracy Doyle⁴, Elena Losina² and Jeffrey Sparks², ¹Mayo Clinic, Rochester, MN, ²Brigham and Women's Hospital, Boston, MA, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Increasing evidence implicates respiratory mucosa in the pathogenesis of rheumatoid arthritis (RA). However, individual respiratory tract diseases, especially of the upper airways, sinuses, and…
Abstract Number: 0587 • ACR Convergence 2021
DMARD Use in Medicare Patients with Rheumatoid Arthritis and Risk of Long-Term Opioid Use
Akhil Sood¹, Yong-Fang Kuo², Jordan Westra² and Mukaila Raji², ¹University of Texas Medical Branch, League City, TX, ²University of Texas Medical Branch, Galveston, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for opioid use. Disease-modifying antirheumatic drugs (DMARDs) have led to better control of disease activity.…
Abstract Number: 0655 • ACR Convergence 2021
Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis
Rosa Morlà¹, Beatriz Frade-Sosa², Núria Sapena³, Roberto Gumucio², Raimon Sanmarti² and Jose A Gomez-Puerta², ¹Hospital Universitari Clinic de Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with different comorbidities. Depression and fatigue are common in RA patients with a prevalence of 17-39-%(1) and 40%(2)…
Abstract Number: 0793 • ACR Convergence 2021
Contributing Factors of Good Outcome in Difficult-to-treat Rheumatoid Arthritis: A Multicenter RA Ultrasound Prospective Observational Cohort Study in Japan
Shin-ya Kawashiri¹, Tohru Michitsuji¹, Yushiro Endo¹, Ayako Nishino¹, Toshimasa Shimizu¹, Remi Sumiyoshi¹, Tomohiro Koga¹, Naoki Iwamoto¹, Kunihiro Ichinose² and Atsushi Kawakami¹, ¹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan
Background/Purpose: The concept of difficult-to-treat rheumatoid arthritis (D2T RA) has emerged as the greatest unmet need in recent years. We have investigated the clinical characteristics…
Abstract Number: 0810 • ACR Convergence 2021
Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis
Carol Hitchon¹, Marie-France Valois², Orit Schieir³, Susan Bartlett², Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Edward Keystone⁷, Janet Pope⁸, Carter Thorne⁹, Diane Tin¹⁰, Vivian Bykerk¹¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montréal, QC, Canada, ³Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Canadian Early Arthritis Cohort, Toronto, ON, Canada
Background/Purpose: Reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We sought to describe work…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.